Longeveron Inc.
NCM: LGVNLive Quote
About Longeveron Inc.
Healthcare
Biotechnology
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 3 clinical trial to treat hypoplastic left heart syndrome; completed phase 2a clinical trial to treat Alzheimer's disease, as well as in phase 2b clinical trial to treat aging frailty. The company was incorporated in 2014 and is headquartered in Miami, Florida.
📊 Fundamental Analysis
Longeveron Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
The company recently reported -39.5% revenue growth, which is negative, indicating a recent decline in revenue.
Return on Equity (ROE) is -164.7%, which indicates that capital utilization is currently under pressure.
At a current price of $1.16, LGVN currently sits at the 51st percentile of its 52-week range (Range: $0.47 - $1.83).
🏥 Financial Health
🔴
Profit Margin
Weak
✅
Debt/Equity
Excellent
🔴
Revenue Growth
Weak
🔴
Return on Equity
Weak
✅
Beta (Risk)
Low Volatility
Key Financials
Market Cap
$24.44M
Trailing P/E
--
Forward P/E
-0.76
Beta (5Y)
-0.19
52W High
$1.83
52W Low
$0.47
Avg Volume
5.68M
Day High
Day Low
📡 Subscribe to ZcoreAI updates
Join the list to get access to:
- Z-Score signals at market open
- New app features and updates
- Exclusive promo for ZcoreAI App